Mathias Hothum is managing director of dievini Hopp Biotech holding GmbH & Co. See contact routes.
Mathias Hothum is managing director of dievini Hopp Biotech holding GmbH & Co. KG, the Hopp family’s life-science investment vehicle in Walldorf, and is described as overseeing the family’s life science activities and investments. Public descriptions say dievini invests patient, evergreen balance-sheet capital directly into biotech, therapeutics, diagnostics, and related areas, with focus on oncology, neurology, infectiology, cell therapy, and pharmaceutical formulations, mainly in Germany and Europe. A 2021 profile said his portfolio then comprised 11 biotech holdings, indicating a long-term, concentrated approach rather than frequent trading. Named portfolio companies and board roles linked to him include Immatics, CureVac, Heidelberg Pharma, Molecular Health, Novaliq, Apogenix, Joimax, and Geuder. Public reporting also shows the Hopp family office acting as a lead investor in Bluecode’s €20 million financing round. Separately, Hopp Family Office has pursued renewable-energy activity through ventures such as Aurinko, though that is broader family-office activity rather than specifically attributed to Hothum. No reliable public source located here provides a
This profile is part of the StartupFundraising investor database: focus, portfolio history, disclosed location and contact routes, refreshed as new filings and rounds are ingested. Founders use it to check fit before reaching out and to find investors in Walldorf.
Investors like Mathias Hothum · Full investor directory · Investor access · Company funding database